SAN DIEGO, May 21, 2021 (GLOBE NEWSWIRE) – Progenity, Inc. (PROG), a biotechnology company with an established track record of success in the development and commercialization of molecular testing products in women’s health, joins the global call for awareness on preeclampsia during pregnancy, the Day World Preeclampsia, Saturday, May 22nd. Preeclampsia is a hypertensive disorder that occurs during pregnancy and is the number two cause of maternal mortality. However, data from a recent survey of women of childbearing age showed that less than half know that high blood pressure is the most common sign of preeclampsia. This points to the urgent need for greater awareness and education of patients about the symptoms of preeclampsia.
In honor of World Preeclampsia Day, Progenity has created two free resources to help support important conversations between patients and doctors about the symptoms of preeclampsia. Talking to patients about preeclampsia is a fact sheet for healthcare providers that offers suggestions on how to start a conversation with patients about preeclampsia, while addressing potential anxiety. The information sheet for patients, Understanding preeclampsia: questions to ask your OB / GYN, is designed to allow patients to recognize symptoms and have a conversation with their doctor as their best advocate.
Preeclampsia is often missed or misdiagnosed because symptoms are very common and occur in nearly 30% of all pregnant women in the United States and can easily be attributed to other causes. This makes it difficult for doctors to differentiate which patients may develop preeclampsia.
Despite rising rates of preeclampsia, there have been no significant advances in diagnostic assessment tools in the United States in decades. However, doctors will soon be able to perform a new plain blood test to rule out the risk of preeclampsia for up to 14 days, modernizing the way patients are assessed. The Preecludia test, developed at a late stage by Progenity, is designed to help doctors differentiate symptomatic patients who have a reduced risk of preeclampsia from those at risk.
We are pleased to play a role in educating physicians and patients on how to best discuss the signs and symptoms of preeclampsia. We believe this is part of our responsibility as an innovator in the area of preeclampsia diagnosis, said Harry Stylli, PhD, CEO, board chairman and co-founder of Progenity. The Preecludia test would be the first of its kind in the United States and is designed to help improve the assessment and management of preeclampsia. We look forward to continuing our commitment to preeclampsia education as we move toward our specific launch later this year.
For more information on Progenitys products and piping, visit www.progenity.com or follow the company on LinkedIn or Twitter.
As for Preecludia
The Progenitys preeclampsia exclusion test, Preecludia, has the potential to be the first such test in the United States to help healthcare providers assess patients who have signs and symptoms of possible preeclampsia. This laboratory-developed test (LDT) is a new multi-analytical protein biomarker assay designed to examine markers of multiple pathophysiological pathways of preeclampsia to assess risk. It runs from a simple blood draw and is designed to address the unmet need for tools to aid in the assessment and management of preeclampsia. Positive performance data from the Preecludia verification study were presented on April 30 at the annual meeting of the American College of Obstetricians and Gynecologists (ACOG). The test is now in the final phase of clinical validation testing, with a specific release scheduled for the second half of 2021.
As for progeny
Progenity, Inc. is a biotechnology company with an established track record of success in the development and marketing of molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular testing designed to improve life by providing useful information to help patients and physicians make medical decisions during key stages of life. The company applies a multi-omic approach, combining genomics, epigenomics, proteomics and metabolomics to its molecular testing products and the development of a set of ingestible research devices designed to provide sampling solutions. accurate diagnosis and medication administration. The vision of the offspring is to transform health care to be more accurate and personal by improving disease diagnoses and improving patient outcomes through localized treatment with targeted therapies. For more information on how Progenity is helping clinicians and patients prepare for life, visit progenity.com.
This press release contains forward-looking statements, which are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, except statements of historical facts included in this press release, including statements about the progress of the development of our preeclampsia exclusion test and its future use by providers to rule out preeclampsia, are statements. prospective. In some cases, you may identify forward-looking statements by terms such as can, could, want, goals, intend, should, could, could, would expect, believe, design, estimate, predict, potential, plan, or the negative of these terms and similar expressions intended to identify prospective statements. These statements involve risks, uncertainties and other known and unknown factors that could cause the Company’s actual results to differ materially from the forward-looking statements expressed or implied in this press release, including acceptance and clinical usefulness of our products, the regulatory developments in the United States Foreign states and countries, our ability to obtain and maintain regulatory approval or authorization of our products on time or at all, and those risks described in Discussion and analysis of financial position and results of transactions in the factors and results of transactions in our annual report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 18, 2021, and other subsequent documents which we submit to the SEC, including, but not limited to, the quarterly reports on Form 10-Q. We demand the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly waive any obligation to update or modify any statement, whether as a result of new information, future events or otherwise, except as required by law.
Contact with the investor:
General Manager, Westwicke ICR
Contact with the media: